Condition: Vanishing White Matter Disease · Sponsor: Calico Life Sciences LLC
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
This description comes directly from the study's public registry record.
Call Center - English · 1-833-250-9660 · vwminfo@mylocalstudy.com
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital /ID# 270960 | Boston, Massachusetts, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Utah /ID# 255624 | Salt Lake City, Utah, United States | Recruiting |
| McGill University Health Centre - Glen Site | Montreal, Quebec, Canada | Recruiting |
| Amsterdam UMC, locatie VUmc /ID# 270955 | Amsterdam, North Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05757141